Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11665488 | 0.78 | L3MBTL1 (0.36) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL18181903 | 0.69 | L3MBTL1 (0.65) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL13211365 | 0.66 | MEN1 (0.55) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL21164762 | 0.66 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL18177823 | 0.66 | ALDH1A1 (0.63) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL11667889 | 0.64 | KDM4E (0.43) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL11327864 | 0.60 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31154491 | 0.59 | FPR2 (0.39) | L3MBTL1SMN1; SMN2HDAC1HDAC2 | |
| SCHEMBL28827067 | 0.59 | SMN1; SMN2 (0.35) | L3MBTL1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL11668052 | 0.58 | CYP3A4 (0.38) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164835-B1 | PROCESS FOR PREPARING TRIAZOLONES | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20100280256-A1 | PROCESS FOR PREPARING TRIAZOLONES | LEE GARY M | 2010-11-04 | — | — | US | disclosed |
| US-7745634-B2 | Process for preparing triazolones | ROCHE PALO ALTO LLC (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2164835-A2 | PROCESS FOR PREPARING TRIAZOLONES | F. Hoffmann-Roche AG (CH) | 2010-03-24 | — | — | EP | disclosed |
| US-20090012304-A1 | preparation of intermediates 3-[3-(4-methyl-5-methylsulfanyl-4H-[1,2,4]triazol-3-ylmethyl)phenoxy]-5-difluoromethyl-benzonitrile derivatives; for making enzyme inhibitors of HIV-1 reverse transcriptase, treating AIDS and HIV-1 syndromes | ROCHE PALO ALTO LLC | 2009-01-08 | — | — | US | disclosed |
| WO-2008145563-A2 | PROCESS FOR PREPARING TRIAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280256-A1 | PROCESS FOR PREPARING TRIAZOLONES | CYP51A1, TNKS, TNKS2 | L3MBTL1 4758/4885SMN1; SMN2 3453/4885ALDH1A1 3022/4885 |
| US-20090012304-A1 | preparation of intermediates 3-[3-(4-methyl-5-methylsulfanyl-4H-[1,2,4]triazol-3-ylmethyl)phenoxy]-5-difluoromethyl-benzonitrile derivatives; for making enzyme inhibitors of HIV-1 reverse transcriptase, treating AIDS and HIV-1 syndromes | POLRMT, TYMS, POLR1G | L3MBTL1 1555/4885SMN1; SMN2 3953/4885ALDH1A1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.